Legal Representation
Attorney
Karl M. Zielaznicki, Esq.
USPTO Deadlines
Next Deadline
1401 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-05-23)
Due Date
May 23, 2029
Grace Period Ends
November 23, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 23, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| May 23, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 7, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 7, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 15, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 31, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jan 31, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 31, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 31, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 31, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 14, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 13, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 13, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 27, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 27, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 27, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 27, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 24, 2022 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Apr 1, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 31, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products for use in the field of neuroscience, namely, for the treatment of neurological and nervous system diseases and disorders; pharmaceutical preparations for the treatment of seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005